FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Company ProfileFreenome, Inc. Common stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
FRNM
Freenome, Inc. Common stock Stock AnalysisComprehensive stock analysis for Freenome, Inc. Common stock (FRNM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisFRNM
FRNM
Freenome, Inc. Common stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
FRNM
Home🔹Stocks🔹Freenome, Inc. Common stock

Freenome, Inc. Common stock

🇺🇸FRNM•NASDAQ

Freenome, Inc. Common stock

🇺🇸FRNM•NASDAQ
Market cap
$130.43M
Sentiment

Your view on FRNM

Mkt Cap
$130.43M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Freenome, Inc. Common stock

Industry
Biotechnology
Sector
Healthcare
CEO
Aaron Elliott
Headquarters
3300 Marina Boulevard, Brisbane, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Aaron Elliott
Headquarters
3300 Marina Boulevard, Brisbane, CA, US
Description

Perceptive Capital Solutions Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Eric Edelman, Adam Leo Stone, and Michael R.

Altman on March 22, 2024 and is headquartered in New York, NY.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Freenome, Inc. Common stock, and the rating behind it. FRNM last traded at $15.99; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Freenome, Inc. Common stock. Starting points for Freenome, Inc. Common stock: beta 0.35 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Freenome, Inc. Common stock. Freenome, Inc. Common stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Freenome, Inc. Common stock. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Freenome, Inc. Common stock. Freenome, Inc. Common stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Freenome, Inc. Common stock valued side by side against its closest peers. Freenome, Inc. Common stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Freenome, Inc. Common stock, and how their positions are changing. At a $130.4M market value, institutional positions materially move Freenome, Inc. Common stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Freenome, Inc. Common stock executives and directors. Shares of Freenome, Inc. Common stock have traded between $9.95 and $14.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Freenome, Inc. Common stock. Freenome, Inc. Common stock is a $130.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Freenome, Inc. Common stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Freenome, Inc. Common stock. Coverage tracks Freenome, Inc. Common stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

More Biotechnology companies

  • PHRM.CNPharmaTher Holdings Ltd.
  • PHRRFPharmaTher Holdings Ltd.
  • PHVSPharvaris N.V.
  • PHYOFIXICO plc
  • PKTXProtoKinetix, Incorporated
  • PLRXPliant Therapeutics, Inc.
  • PLRZPolyrizon Ltd.
  • PLURPluri Inc.
  • PLXProtalix BioTherapeutics, Inc.
  • PLYXPolaryx Therapeutics, Inc. Common Stock
  • PMCBPharmaCyte Biotech, Inc.
  • PMNProMIS Neurosciences, Inc.

ETFs holding Freenome, Inc. Common stock

Largest holders, then the funds most concentrated in FRNM · % = share of the fund

  • ARKGARK Genomic Revolution ETF0.53%
  • SCHASchwab U.S. Small-Cap ETF0.02%
  • ITOTiShares Core SP Total US Stock Market ETF0.00%
  • ONEQFIDELITY NASDAQ COMPOSITE INDEX ETF0.01%
  • SCHBSchwab U.S. Broad Market ETF0.00%
  • TNXTT. Rowe Price Innovation Leaders ETF0.19%

News

Latest Market News